Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients.

Keywords: COVID-19; CXCL9; Cytokine; Dexamethasone; Inflammation; Serology EN COVID-19 CXCL9 Cytokine Dexamethasone Inflammation Serology 1 3 3 09/12/22 20220908 NES 220908 Supplementary Information The online version contains supplementary material available at https://doi.org/10.1186/s12967-022-03583-5. " I" or " C" refers to analytes measured by Olink Inflammation I panel or Cardiovascular II panel, respectively Focusing on markers differentially regulated in COVID-19 patients, we observed a unique biomarker profile in patients depending on their therapeutic journey. 1 A (lower) Heatmap analysis comparing fold change for protein biomarker levels in baseline samples of COVID-19 patients versus age/sex-matched healthy controls (HC). [Extracted from the article]